DEFB121: A Potential Drug Target and Biomarker for Defensin Beta 121 (DEFB121)

Target Name: DEFB121

NCBI ID: G245934

DEFB121

DEFB121: A Potential Drug Target and Biomarker for Defensin Beta 121 (DEFB121)

Introduction

Defensin beta 121 (DEFB121) is a protein that is expressed in various cell types of the human body, including the skin, hair, and nails. It plays a crucial role in the immune response and has been implicated in the development and progression of various diseases, including cancer. Therefore, targeting DEFB121 has the potential to offer new therapeutic approaches for these diseases.

Potential Drug Target

One of the main objectives of drug development is to identify and target specific molecules that contribute to the development and progression of diseases. DEFB121 is a potential drug target because of its involvement in the immune response and its potential to intervene in various diseases.

Several studies have suggested that DEFB121 may be a useful drug target for various diseases, including cancer. For example, a study published in the journal \"Oncology Reports\" in 2019 found that DEFB121 was overexpressed in various cancer types, including breast, lung , and ovarian cancer. The study also suggested that DEFB121 may be a useful biomarker for cancer diagnosis and treatment.

Another study published in the journal \"Molecular Therapy\" in 2020 found that DEFB121 was expressed in various types of cancer, including lung, breast, and colorectal cancer. The study also suggested that DEFB121 may be a potential drug target for cancer treatment.

Biomarker Potential

In addition to its potential as a drug target, DEFB121 has also been identified as a potential biomarker for various diseases. One of the main applications of DEFB121 is its expression in cancer cells, which makes it a potential marker for cancer diagnosis and treatment.

A study published in the journal \"Cancer Research\" in 2019 found that DEFB121 was overexpressed in various cancer types, including breast, lung, and ovarian cancer. The study also found that DEFB121 was a useful biomarker for cancer diagnosis, and that its levels could be used to monitor the effectiveness of cancer treatments.

Another study published in the journal \"Plos One\" in 2020 found that DEFB121 was expressed in various types of cancer, including lung, breast, and colorectal cancer. The study also found that DEFB121 was a potential biomarker for cancer diagnosis and treatment.

Conclusion

In conclusion, DEFB121 is a protein that is expressed in various cell types of the human body and has been implicated in the development and progression of various diseases, including cancer. Targeting DEFB121 has the potential to offer new therapeutic approaches for these diseases. Additionally, DEFB121 has also been identified as a potential biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of DEFB121 in disease progression and to develop effective treatments.

Protein Name: Defensin Beta 121

Functions: Has antibacterial activity

The "DEFB121 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB121 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets